Francois Nader - 19 Jul 2022 Form 4/A - Amendment Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Director
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
19 Jul 2022
Net transactions value
+$500,020
Form type
4/A - Amendment
Filing time
13 Sep 2022, 16:27:51 UTC
Date Of Original Report
25 Jul 2022
Previous filing
13 Jun 2022
Next filing
05 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Purchase $176,000 +50,000 $3.52 50,000 19 Jul 2022 Direct F1
transaction TALS Common Stock Purchase $188,240 +52,000 +104% $3.62 102,000 20 Jul 2022 Direct F2
transaction TALS Common Stock Other $0 -248,432 -63% $0.000000 147,255 21 Jul 2022 By Francois Nader 2020 Trust F3, F4, F8
transaction TALS Common Stock Other $0 +248,432 $0.000000 248,432 21 Jul 2022 By FN TALS LLC F3, F5
transaction TALS Common Stock Purchase $135,780 +36,500 +36% $3.72 138,500 21 Jul 2022 Direct F6
transaction TALS Common Stock Other $0 -138,500 -100% $0.000000* 0 25 Jul 2022 Direct F7
transaction TALS Common Stock Other $0 +138,500 +56% $0.000000 386,932 25 Jul 2022 By FN TALS LLC F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration.
F4 These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person''s spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F5 These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F6 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7 Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration.
F8 This amendment is being filed solely to correct the number of shares reported by the Francois Nader 2020 Trust, which was incorrectly reported due to an administrative error.